Chronic Heart Failure Market: Novel Therapies Reshape a Traditionally Genericized Landscape
The chronic heart failure (CHF) treatment landscape is undergoing a significant transformation. While historically dominated by generic therapies targeting neurohormonal pathways, recent years have seen the emergence of novel branded treatments that offer improved outcomes and address previously unmet needs.
The market is now driven by the uptake of SGLT-2 inhibitors such as Farxiga and Jardiance, which have demonstrated benefits across both HFrEF and HFpEF populations. Entresto continues to grow, bolstered by strong guideline recommendations and label expansions. Meanwhile, new entrants like Inpefa and Verquvo are carving out niche roles, and GLP-1 agonists such as semaglutide and tirzepatide are poised to address the obesity-related HFpEF segment.
This report provides a comprehensive analysis of the CHF market across the US, Japan, and five major European markets, with a 10-year patient-based forecast and deep dives into pipeline innovation, treatment guidelines, and evolving market dynamics.
In this report we cover:
- Key growth drivers: Uptake of SGLT-2 inhibitors, label expansions, and increasing prevalence of CHF.
- Promising therapies: Entresto, Farxiga, Jardiance, Inpefa, Verquvo, semaglutide, and tirzepatide.
- Market evolution: Shift from generic neurohormonal therapies to branded, mechanism-specific treatments.
